[HTML][HTML] Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
N Gagelmann, F Passamonti, C Wolschke… - …, 2022 - ncbi.nlm.nih.gov
Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an
important preventive option against coronavirus disease 2019 (COVID-19), especially in …
important preventive option against coronavirus disease 2019 (COVID-19), especially in …
Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is a malignancy of CD5+ B cells that is characterized
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …
by the accumulation of small, mature-appearing lymphocytes in the blood, marrow and …
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
AR Mato, LE Roeker, N Lamanna… - Blood, The Journal …, 2020 - ashpublications.org
Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia
(CLL) patients may be at particularly high risk of infection and poor outcomes related to …
(CLL) patients may be at particularly high risk of infection and poor outcomes related to …
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
L Scarfò, T Chatzikonstantinou, GM Rigolin… - Leukemia, 2020 - nature.com
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by
immunodeficiency. Hence, patients with CLL might be considered more susceptible to …
immunodeficiency. Hence, patients with CLL might be considered more susceptible to …
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
C Perry, E Luttwak, R Balaban, G Shefer… - Blood …, 2021 - ashpublications.org
Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and
patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines …
patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines …
Ibrutinib treatment improves T cell number and function in CLL patients
M Long, K Beckwith, P Do, BL Mundy… - The Journal of …, 2017 - Am Soc Clin Investig
BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting
Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative …
Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative …
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
T Chatzikonstantinou, A Kapetanakis, L Scarfò… - Leukemia, 2021 - nature.com
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus
disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression …
disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression …
[HTML][HTML] Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
Studies describing SARS-CoV-2 immune responses following mRNA vaccination in
hematology malignancy (HM) patients are virtually non-existent. We measured SARS-CoV-2 …
hematology malignancy (HM) patients are virtually non-existent. We measured SARS-CoV-2 …